Molecular epidemiological study of clinical Acinetobacter baumannii isolates: phenotype switching of antibiotic resistance

Table 2 Antibiotic susceptibility of clinical Acinetobacter baumannii isolates

Number of isolate	10-10	10-18	29-43	29-4	14-91	14-81
Date of isolation	2-Aug	16-Aug	19-Jul	18-Aug	9-Jun	7-Jul
Time of isolation	PM 02:38:55	PM 03:10:10	PM 04:21:03	PM 02:47:06	AM 09:12:47	AM 10:18:53
Diagnosis	pneumonia	Soft tissue infection	pneumonia	Catheter-related infection	pneumonia	pneumonia
Specimens	Sputum, tracheal aspirate (suction)	abscess	Sputum, tracheal aspirate (suction)	Tip of central catheter	Sputum, tracheal aspirate (suction)	Sputum, tracheal aspirate (suction)
Antibiotic	Minimum inhibitory	concentrations	(ug/mL)
AN	8	128	8	128	8	64
SAM	32	128	32	128	32	128
CTZ	8	64	8	64	8	32
LVF	2	128	2	128	2	64
IMP	2	16	2	16	2	16
PIP-TAZ	8	256	8	256	8	256
CRO	8	128	8	128	8	64
CFP	8	256	8	256	8	128
MEP	4	32	4	32	4	16

Notes: The susceptibility tests were performed using the Vitek-2 GN card (Biomerieux, Marcy l'Etoile, France). The results were interpreted using the CLSI breakpoints (Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility testing; Twenty-First Information Supplement. CLSI document M100-S21, CLSI, Wayne, PA; 2011).
AN: amikacin; SAM: ampicillin-sulbactam; CTZ: ceftazidime; LVF: levofloxacin; IMP: imipenem-cilastatin; PIP-TAZ: piperacillin-tazobactam; CRO: ceftriaxone; CFP:cefepime; MEP: meropenem; colistin and tigecycline and polymyxin B were not provided by Vitek-2 System.

ISSN: 1476-0711